Clinical outcomes by best response on treatment
Outcome . | Observed outcome by best response on treatment . | RD compared with patients with best response of NR . | |||||
|---|---|---|---|---|---|---|---|
| CR (n = 163) . | CRh (n = 52) . | CRL (n = 142) . | NR (n = 484) . | CR vs NR . | CRh vs NR . | CRL vs NR . | |
| TI | |||||||
| TI-56, % (95% CI) | 96.3%∗ (92.2-98.6) | 92.3%∗ (81.5-97.9) | 27.5%† (20.3-35.6) | 22.3% (18.7-26.3) | 74.0 (69.3-78.7) | 70.0 (61.9-78.1) | 5.2 (–3.1 to 13.4) |
| TI-112, % (95% CI) | 81.0%∗ (74.1-86.7) | 63.5%∗ (49.0-76.4) | 9.9% (5.5-16.0) | 8.7% (6.3-11.5) | 72.3 (65.8-78.8) | 54.8 (41.5-68.1) | 1.2 (–4.3 to 6.7) |
| Median longest TI period (IQR), d | 287 (133-596) | 146 (84.5-227.5) | 28.5 (14-59) | 26 (11-50) | |||
| Other clinical outcomes | |||||||
| Febrile neutropenia, % (95% CI) | 20.3%∗ (14.4-27.2) | 30.8% (18.7-45.1) | 34.5% (26.7-42.9) | 36.2% (31.9-40.6) | –15.9 (–23.4 to –8.4) | –5.4 (–18.6 to 7.9) | –1.6 (–10.6 to 7.3) |
| Severe infection, % (95% CI) | 23.9%∗ (17.6-31.2) | 34.6% (22.0-49.1) | 50.0% (41.5-58.5) | 46.9% (42.4-51.5) | –23.0 (–30.9 to –15.1) | –12.3 (–26 to 1.4) | 3.1 (–6.2 to 12.4) |
| Severe bleeding, % (95% CI) | 5.5%† (2.6-10.2) | 3.8% (0.5-13.2) | 10.6% (6.0-16.8) | 13.0% (10.1-16.3) | –7.5 (–12.1 to –2.9) | –9.1 (–15.2 to –3.1) | –2.5 (–8.3 to 3.4) |
Outcome . | Observed outcome by best response on treatment . | RD compared with patients with best response of NR . | |||||
|---|---|---|---|---|---|---|---|
| CR (n = 163) . | CRh (n = 52) . | CRL (n = 142) . | NR (n = 484) . | CR vs NR . | CRh vs NR . | CRL vs NR . | |
| TI | |||||||
| TI-56, % (95% CI) | 96.3%∗ (92.2-98.6) | 92.3%∗ (81.5-97.9) | 27.5%† (20.3-35.6) | 22.3% (18.7-26.3) | 74.0 (69.3-78.7) | 70.0 (61.9-78.1) | 5.2 (–3.1 to 13.4) |
| TI-112, % (95% CI) | 81.0%∗ (74.1-86.7) | 63.5%∗ (49.0-76.4) | 9.9% (5.5-16.0) | 8.7% (6.3-11.5) | 72.3 (65.8-78.8) | 54.8 (41.5-68.1) | 1.2 (–4.3 to 6.7) |
| Median longest TI period (IQR), d | 287 (133-596) | 146 (84.5-227.5) | 28.5 (14-59) | 26 (11-50) | |||
| Other clinical outcomes | |||||||
| Febrile neutropenia, % (95% CI) | 20.3%∗ (14.4-27.2) | 30.8% (18.7-45.1) | 34.5% (26.7-42.9) | 36.2% (31.9-40.6) | –15.9 (–23.4 to –8.4) | –5.4 (–18.6 to 7.9) | –1.6 (–10.6 to 7.3) |
| Severe infection, % (95% CI) | 23.9%∗ (17.6-31.2) | 34.6% (22.0-49.1) | 50.0% (41.5-58.5) | 46.9% (42.4-51.5) | –23.0 (–30.9 to –15.1) | –12.3 (–26 to 1.4) | 3.1 (–6.2 to 12.4) |
| Severe bleeding, % (95% CI) | 5.5%† (2.6-10.2) | 3.8% (0.5-13.2) | 10.6% (6.0-16.8) | 13.0% (10.1-16.3) | –7.5 (–12.1 to –2.9) | –9.1 (–15.2 to –3.1) | –2.5 (–8.3 to 3.4) |
%, percentage of patients with the listed outcome on treatment; IQR, interquartile range; n, number of patients with the best response in the column header on treatment; RD, risk difference.
P < .01 for comparison with NR by logistic regression adjusting for drug and baseline transfusion dependence status.
P < .05 for comparison with NR by logistic regression adjusting for drug and baseline transfusion dependence status. See supplemental Table 2 for details.